EMVC
NEUTRALEMV Capital Announces PDMR Dealing
The venture capital firm announces a PDMR has transferred shares for portfolio consolidation purposes.
EMV Capital
60.50GBX
0.00%
Market Cap
16.92M
Volume
10
0% of avg
P/E Ratio
-1698.96
EPS (TTM)
-0.04
Beta
0.56
Day Range
59.00p - 59.00p
52 Week Range
34.00p60.50p62.00p
60.50p
Upcoming Events
EMVC
NEUTRALEMV Capital Announces Fundraising for Portfolio Company Sofant Technologies
The deep tech and life sciences VC investment group EMV Capital has announced a successful £6.25 million equity fundraising for its portfolio company, Sofant Technologies, a developer of low-power RF MEMS beamforming solutions.
EMVC
NEUTRALEMV Capital Announces Director Share Transfer
The deep tech and life sciences VC investment group announces a director has transferred shares for portfolio consolidation purposes.
EMVC
NEUTRALEMV Capital Announces Fundraising and Business Update for Portfolio Company Wanda Health
The deep tech and life sciences VC investment group EMV Capital has announced a successful fundraising for its portfolio company Wanda Health, along with an update on the company's commercial progress and market outlook.
EMVC
NEUTRALEMV Capital Announces Share Issue and Director Dealings
The deep tech and life sciences VC investment group has issued new shares to directors and a PDMR, and certain directors have purchased additional shares.
EMVC
NEUTRALEMV Capital Announces Director Dealings
The asset management firm has announced a change in shareholding by one of its directors.
EMVC
NEUTRALEMV Capital Expands Senior Finance Leadership Team
The deep tech and life sciences VC investment group is expanding its senior finance leadership team with the appointment of a new Group CFO and the creation of a Portfolio CFO role.
EMVC
NEUTRALEMV Capital Hosts Virtual Meet the Portfolio Event
The venture capital firm is hosting a virtual event to provide investors with insights into two of its portfolio companies.
EMVC
BADEMV Capital Reports Challenging H1 2025 Amid Market Headwinds
The venture capital firm reported a challenging first half of 2025, with decreased revenue and a significant drop in cash position amid persistent market headwinds and limited capital availability.
EMVC
GOODEMV Capital Acquires Assets of Destiny Pharma's XF-73 Antibiotic Platform
The venture capital firm has acquired the assets of a novel antibiotic platform from a company in liquidation, with the potential to develop a product that could address the growing threat of antimicrobial resistance.